Increasing access to cancer trials in Minnesota (InACT-MN)

项目摘要/摘要 在与明尼苏达大学共济会癌症中心的合作下，医学博士布里特·埃里克森 制定了一项研究战略，利用她在临床试验设计和执行方面的技能，以及她 作为一名导师和教育者的经验，以改善共济会癌症内NCI临床试验的机会 中心和整个明尼苏达州。 她将开放并参加更多妇科肿瘤学NCI预防和治疗试验。她会的 与其他疾病现场负责人和合作小组主要调查人员合作，以便确定优先顺序 在明尼苏达大学成功几率最高的试验。她将成为社区诊所 共济会癌症中心的试验联络人，在社区开展妇科肿瘤专科NCI试验 在临床试验领导和积累的过程中，站点和指导社区肿瘤学家。这 社区扩展将通过M Health Fairview癌症服务热线进行，这是一种新的临床实体 成立于2019年，是明尼苏达大学和美景大学共同努力的结果，是一家非 盈利的医疗保健服务。M Health Fairview癌症服务线包括七个社区站点 整个明尼阿波利斯/圣保罗大都市区，提供了一个打破传统 学术和社区医学之间的障碍，与增加获得 治疗性临床试验。癌症服务热线还延伸到了中部农村地区的两个服务不足的地点 明尼苏达州有大量的美洲原住民人口，临床试验准入历来有限。在这些地方 地点-与社区肿瘤学家、现有的NCORP基础设施和先前存在的合作伙伴合作 通过明尼苏达州癌症临床试验网络(自2017年以来由州政府资助的网络，位于 明尼苏达大学)-埃里克森博士将在扩大NCI临床试验准入的使命中发挥不可或缺的作用 全是明尼苏达人。 埃里克森博士的经验以及目前在当地和全国范围内参与NCI临床试验工作的经验使她成为 提议的计划的理想人选。除了扩大试用范围外，她还将继续她的本地和 为国家服务。这包括担任癌症议定书审查委员会的成员和联合主席。 共济会癌症中心内的妇科肿瘤学跨学科网站委员会。它还 担任子宫体委员会和癌症预防和控制的核心成员 NRG肿瘤学委员会。她还将继续担任#年第二阶段DCP审判的国家PI 依西美坦治疗子宫内膜癌(UWI-2016-08-01)和一项新合作小组研究的国家PI，NRG- GY026正在探索HER2导向疗法在HER2阳性子宫内膜癌中的作用，将开业 2022年6月，计划应计525名患者。

PROJECT SUMMARY/ABSTRACT In collaboration with the Masonic Cancer Center of the University of Minnesota, Britt Erickson, MD, has developed a research strategy that will leverage her skills in clinical trial design and execution, as well as her experience as a mentor and educator, to improve access to NCI clinical trials within the Masonic Cancer Center and throughout greater Minnesota. She will open and enroll to more NCI prevention and therapeutic trials in gynecologic oncology. She will collaborate with other disease site leaders and cooperative group principal investigators in order to prioritize trials with the highest chances for success at the University of Minnesota. She will be the community clinical trial liaison for the Masonic Cancer Center, opening gynecologic oncology specific NCI trials at community sites and mentoring community oncologists in the process of clinical trial leadership and accrual. This community extension will be done through the M Health Fairview Cancer Service Line, a novel clinical entity established in 2019 as a result of combining efforts between the University of Minnesota and Fairview, a non- profit healthcare delivery service. The M Health Fairview Cancer Service Line includes seven community sites throughout the Minneapolis/St Paul metropolitan area and presents an opportunity to break down traditional barriers between academic and community medicine, uniting with a common vision of increasing access to therapeutic clinical trials. The Cancer Service Line has also extended to two underserved sites in rural central Minnesota with a substantial Native American population and historically limited clinical trial access. At these locations—working with community oncologists, existing NCORP infrastructure, and pre-existing collaborations through the Minnesota Cancer Clinical Trials Network (a state funded network since 2017, housed at the University of Minnesota)—Dr. Erickson will be integral to the mission of expanding NCI clinical trial access to all Minnesotans. Dr. Erickson’s experience and current involvement locally and nationally in NCI clinical trial work make her an ideal candidate for the proposed plan. In addition to expanding trial availability, she will continue her local and national service. This includes serving as a member of the Cancer Protocol Review Committee and as co-chair of the Gynecologic Oncology Interdisciplinary Site Committee within the Masonic Cancer Center. It also involves serving as a core member of the Uterine Corpus Committee and Cancer Prevention and Control Committee of NRG oncology. She will also continue her work as the national PI of the phase II DCP trial of exemestane in endometrial cancer (UWI-2016-08-01) and national PI of a new cooperative group study, NRG- GY026, which is exploring the role of HER2 directed therapy in HER2 positive endometrial cancer, set to open in June of 2022 with planned accrual of 525 patients.